Biolidics (SGX:8YY) Operating Cash Flow per Share : S$-0.00 (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Biolidics Operating Cash Flow per Share?

Biolidics's operating cash flow per share for the three months ended in Dec. 2024 was S$0.00. Biolidics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2024 was S$-0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 51.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 34.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Biolidics's Operating Cash Flow per Share or its related term are showing as below:

SGX:8YY' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -39.1 Med: 15.7 Max: 51
Current: 51

During the past 10 years, Biolidics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 51.00% per year. The lowest was -39.10% per year. And the median was 15.70% per year.

SGX:8YY's 3-Year OCF Growth Rate is ranked better than
89.02% of 173 companies
in the Medical Diagnostics & Research industry
Industry Median: 3 vs SGX:8YY: 51.00

Biolidics Operating Cash Flow per Share Historical Data

The historical data trend for Biolidics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolidics Operating Cash Flow per Share Chart

Biolidics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.01

-0.02

-0.01

Biolidics Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Biolidics's Operating Cash Flow per Share

For the Diagnostics & Research subindustry, Biolidics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolidics's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biolidics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biolidics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Biolidics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Biolidics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-2.313	/	981.259
	=	-0.00

Biolidics's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Dec. 2024 )	=	Cash Flow from Operations (Q: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
	=	-0.771	/	1690.759
	=	-0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-0.00

Biolidics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Biolidics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolidics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biolidics Ltd (SGX:8YY) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Howard Road, No. 11-09 Novelty BizCentre, Singapore, SGP, 369585

Website

https://www.biolidics.com

Biolidics Ltd is engaged in technology development, technology transfer, marketing, sales, and distribution of biomedical technology, life, and medicine science-related products and services, and investment holding. The company's business segments are: Cancer, Infectious Diseases, E-sport, and Corporate. The company generates the majority of its revenue from E-sport segment, which involves identifying and assessing potential collaboration partners, technology, digital platforms, products, and services related to E-Sports.. Its operations are spread across Singapore, Japan, China, Europe, the United States, Hong Kong, the Philippines, Indonesia, and Others.

Biolidics Headlines

No Headlines